BriaCell Therapeutics Corp. Announces Completion of Shares for Debt Issuance
August 17 2020 - 7:43PM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, announces that further to its news release dated August 11,
2020, it has received the approval of the TSX Venture Exchange for
the shares for debt transaction, to settle the aggregate of
$374,000 in indebtness of the Company, through the issuance of
50,000 common shares of the Company (each, a
"
Share") at a deemed price of $7.48 per Share
("
Debt Settlement").
All securities issued pursuant to the Debt
Settlement are subject to a hold period of four-months and one
day.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024